Andria Riti

While public drug programs across Canada have adopted biosimilar transition or “switching” policies to help sustain their drug plans and expand coverage for innovative new treatments, private market adoption of biosimilars has been slower.   That's why Biosimilars Canada is launching its new #SaveBigWithBiosimilars campaign to educate Canadian businesses about the benefits of adopting biosimilar transition policies for their employee health benefit plans.   “As cost pressures continue to increase for all businesses, expanding the use of biosimilars should not be overlooked as an important solution to help employers sustain their drug programs and transform the benefits they provide for their employees,” explains Jim Keon, President of Biosimilars Canada.   Learn more about the campaign, and find out how private drug plans can #SaveBigWithBiosimilars. Read the press release here: https://lnkd.in/e3jWubPg Read the campaign page here: https://lnkd.in/eSXCCz8D #GlobalBiosimilarsWeek #GBW24

36

Great insights so far, recognizing habits that may hold you back in your career. It's not too late to join the ISPE Canada Women in Pharma Book Club! Join me in these engaging discussions! #WomenInPharma #BookClub #ProfessionalDevelopment #JoinUs

17

What is your 5 year career plan? Mine was to work in digital health. I’m now doing it in the context of clinical trials thanks to a partnership between Novartis Canada and Innodem Neurosciences. What is my plan for the next 5 years? Not entirely sure yet but I’m confident I’ll get some good clues at e-Health Conference and Tradeshow 2024. Can’t wait to interact with the delegates and various experts in the field. #DigitalHealth, #MedicalAffairs, #eHealth2024

242

39 Comments

Q&A with Michel Robidoux of Sandoz Canada CGPA: You’re the Vice-Chair of the CGPA. What’s the most important part of your job? Michel: Making patient care more affordable across the country. Generic medication is as safe and effective as the brand-name versions, but costs significantly less. In fact, some of the most prescribed generic medicines come with a price tag that's 90% lower than the same brand-name medication. That means 10 different patients can be treated for the same cost treating just one patient with the brand-name version, so our work has huge impact on both affordability and access to care. CGPA: And you’re also the President and General Manager of Sandoz Canada, which is headquartered in Quebec. How important is the generic pharmaceutical industry to your province? Michel: Extremely important. The industry employs thousands of Quebecers in life-sciences, technology and manufacturing jobs. These are the kinds of jobs that support our communities and stimulate our economy. CGPA: In our last interview with your colleague, Michael B. Sine, we talked about the fact that Ontario would save more than $409 million dollars if it increased its use of generics by only 1%. How much would Quebec save if it did the same thing? Michel: Next to Ontario, Quebec would stand to save the most by increasing its use of generics. A 1% increase alone would translate to $284 million in savings. Overall, the majority of Quebecers understand the importance of generics and are committed to supporting the industry. In fact, 79% of all prescriptions in Quebec are filled with generic medications—that’s more than any other province in the country. CGPA: Sounds like the rest of Canada could learn a thing or two from the people of Quebec. Michel: Of course! After all, we do have the best food, the best nightlife and the best hockey team. CGPA: I’m sure there are a lot of Toronto Maple Leafs fans who would disagree. Michel: We are all Canadian after all…so let's bring the Cup back to Canada.

51

🧪 Explore the latest insights on Gen-AI Pharma from FDA, EMA, and Health Canada in Gramener's blog post. Discover how AI is reshaping the pharmaceutical landscape and accelerating drug development. Explore the future of healthcare  💊 Read more here: https://lnkd.in/e33jbcs3 Ranjeeta B. #blog #genaipharma #healthtech #genaiinhealthcare #gramener

10

This report, commissioned by the Adult Vaccine Alliance, aims to understand the value of adult vaccines in Canada, and its study results are truly noteworthy. For every dollar invested in adult vaccines, there is an estimated average return of $3.41 in productivity gains and averted healthcare costs. As we consider the value of adult vaccines in Canada, the report emphasizes the importance of increased funding and broader participation in adult immunization initiatives to yield substantial benefits for the healthcare system and the economy. 

21

2 Comments

As you may know, Digital tools and AI are revolutionizing biopharma validation in several impactful ways. Joins Us on September 26, 2024 at High Park Brewery, Toronto to discuss a such exciting topic. #ispecanada #ai #validation #csv #quality #compliance #automation #pharma4point0 MIVADO GlobalPerformance ISPE Canada Affiliate ISPE Canada Emerging Leaders ISPE Canada Women in Pharma

5

1 Comment

Want to learn about the steps and process for getting new drugs approved in Canada? Learn about the basics of drug discovery and clinical trials in this 1 hour webinar with Dawn Richards, PhD, Director of Patient and Public Engagement at Clinical Trials Ontario (CTO) and CAPA Vice-President on April 27, 2024 from 1:00 pm to 2:00 pm EDT. This will be the first of a three part series that explains the process in Canada from drug discovery to getting the drugs covered by various public and private insurance plans. Register using this link https://buff.ly/4cSG3Vm or the link in our bio We will be recording the webinar and will send a copy to those who have registered. #CAPA #CanadianArthritisPatientAlliance #Arthritis #InflammatoryArthritis #Osteoarthritis #ClinicalTrials #ClinicalTrialsOntario #DrugDiscovery #CreakyJoints #GlobalHealthyLivingFoundation

5

Join our esteemed panel of experts including Pamela Fralick for the upcoming webinar on May 29: 🔔 **National Pharmaceutical Congress Spring Webinar: Unpacking Bill C-64 – Myths, Realities, and the Future of Canadian Pharmacare** Amidst active discussions on Canada's proposed national pharmacare program, we invite you to a vital session aimed at clarifying the complexities of Bill C-64. Engage in a deep dive into the pivotal issues central to this national debate. **What to Expect:** - **Expert Panel Discussion:** Gain insights from Dr. Mihai (Mike) Csaki, patient advocate Zal Press, and consultant Pamela Fralick on the pressing issues such as drug shortages, impacts on workplace benefits, and the broader pharmaceutical industry. - **Fact vs. Fiction:** Understand the myths and realities of how national pharmacare could transform Canadian healthcare. - **Comparative Insights:** Examine global universal drug plans to gauge potential outcomes of the proposed policy. - **Interactive Q&A Session:** Pose your questions to healthcare leaders during a live session moderated by Mitchell Shannon and Ben Parry, with background research by the NPC Institute. **Details:** - 📅 **Date:** May 29, 2024 - 🕒 **Time:** 11:00 a.m. EDT - 📍 **Location:** Online – accessible globally This webinar is essential for healthcare managers, executives, policymakers, and anyone with an interest in Canadian healthcare reform. Whether you support, oppose, or are simply seeking more information on Bill C-64, this event will offer crucial insights. ✅ **Register now:** [Secure your spot](https://lnkd.in/g2jtdYWc) 👥 **Share this event** with colleagues and others who might benefit from this important discussion. --- We look forward to exploring these critical issues with you. Use the space below to initiate discussions and prioritize your questions for our live session. #lifesciences #leadership #HealthcareReform #NationalPharmaceuticalCongress #Webinar #CanadianHealthcare #BillC64 #NPC2024

5

A well-attended session with great insights: from "doing the job you were hired to do" (even if you are not quite sure how to do it), to performing using your strengths, not what the previous person necessarily did, hiring your own "board of directors" to guide you during tough challenges or smoothing the rough patches. A successful get-together, indeed.

26

1 Comment

Speaking duty is ✅ I had a great time, sharing and learning during this 3 days #whysummit. I've connected with many great people; let's make sure we can make it stick and stay in contact! Here are some of my learnings: The business environnement is in tough waters, with less funding available, but we have to embrace it and use the moment as a catalyst to transformation and improving our ways of working There's no excuse to not use data in decision making now, even prioritization can be assessed based on the measures of value added vs ease of implementation AI is still not being deployed and used across all companies. More openness, collaboration and upskilling is needed Project/Program/Portfolio managers are positioned in a unique place to be silo-buster and must act on it Theres a shift a focus on skills from technical to soft skills and these are center of success for teams and organizations

96

Excited to attend this year’s Canadian Immunization Conference #CIC2024CCI hosted by the @Canadian Public Health Association (CPHA). This conference brings together experts and thought-provoking speakers to discuss the latest advancements in #immunization research, policies, and practices. At #GSKCanada, we believe that prevention is the best medicine – for patients, society, the health system and the economy in Canada. By investing in preventive measures, we can achieve better health outcomes and contribute to the overall well-being and prosperity of our communities. As we all think about how to help people live healthier lives, there is a clear opportunity to invest in #healthcare – enabling earlier action to prevent, diagnose and treat disease for all Canadians. Let's seize this opportunity to build a healthier and thriving nation. #AheadTogether

39

2 Comments

💡 Did you know? Biosimilar switching policies have a significant impact on the cost of specialty drugs. Here's how: Biosimilars, which are highly similar versions of expensive biologics, can lead to substantial cost savings. For instance, in Ontario, a non-medical biosimilar substitution policy was projected to save $238.6 million in just two years. When an adalimumab biosimilar hits the market, these savings could increase to $645.9 million over three years! 🌱💰 But what about patients? While system-wide costs drop, patient out-of-pocket spending doesn’t always follow suit. In some cases, out-of-pocket costs remain the same, though biosimilar claims were found to be about 8% lower than their reference biologics. To fully maximize savings while protecting patient interests, policymakers need to balance cost, access, and clinical outcomes. With thoughtful implementation, biosimilar policies can offer tremendous financial benefits while maintaining high standards of care. #Biosimilars #HealthcareSavings #SpecialtyDrugs #PharmaceuticalPolicy #PatientCare #DrugReimbursement #HealthcareInnovation #CostSavings #RxNavigatorSolutions Let’s continue the conversation about the future of biosimilars and their impact! 👇

2

For anyone looking to improve their questioning techniques, "The Art of Asking Smarter Questions" from Harvard Business Review is a must-read. This article delves into how asking the right questions can drive better decision-making, foster innovation, and enhance problem-solving. It provides practical strategies for refining your inquiry skills, which are essential for leaders and teams aiming to achieve greater clarity and insight. Read it to learn how to transform your approach to questioning and unlock deeper understanding and creativity in your work. Enjoy!

9

1 Comment

BioPharma Services Achieves Another Milestone in Quality Excellence 🏆 We’re excited to announce the successful completion of an FDA Good Clinical Practice (GCP) inspection at our Toronto facility. The weeklong audit concluded with no Form 483 issued.  This thorough inspection reinforces our commitment to safeguarding study participants, maintaining data reliability, and upholding the highest standards of integrity in our clinical trial processes. BioPharma Services remains dedicated to conducting research that meets the stringent requirements of health organizations worldwide. Read more here 👇 https://hubs.li/Q02QXTW10 BioPharma Services Inc. specializes in #Phase1 clinical trials, bioavailability, bioequivalence, First-in-Human and Human Abuse Potential Studies (#HAP). Let our world-renowned #Pharmacokinetics team execute your next clinical trial with confidence. . . . #clinicalresearch #clinicalstudies #clinicaltrials #bioanalsysis #cro #clinicaltrials #Biopharma #drugdevelopment #biotech #pharmaceuticalindustry

21

1 Comment

Drug Sponsors Benefit from New Flexible Scientific Advice Service for Faster Trial Guidance and Cost Reduction The Scientific Advice program by Canada's Drug Agency has introduced a new flexible service for drug sponsors, offering expedited feedback on pivotal trial designs within just four weeks, significantly reducing waiting times. This initiative, introduced to streamline the drug development process, also features a lower fee for faster advice. While the flexible option is designed for sponsors seeking quick guidance, the standard Scientific Advice process remains available, with an option to shorten the review period from 14 to 8 weeks. This initiative reflects efforts to enhance efficiency and flexibility in drug development, supporting pharmaceutical companies in navigating clinical evidence plans. For more details please click the link! https://lnkd.in/dcnsx2Vf #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

2

Today marks the start of #GaucherAwarenessMonth. Gaucher is a rare, progressive disease with symptoms that worsen over time. Yet, patients with type 1 Gaucher disease, the most common form, can experience diagnostic delays up to 10 years. It's important to highlight patient stories in rare disease, here's one. #rareispowerful #raredisease #findthezebra

2

Key take aways from Day 1 of the 8th Annual Patient-Centered Approach to Clinical Trials Conference (hosted by Colorectal Cancer Canada): - We need to stop thinking in terms of a perceived duality of "research patients" and "regular patients" within our healthcare systems in order to increase and enhance care universally in #Canada. - Shift the paradigm to "Research IS Care" in Canada. - Need to implement long-term funding plans for research projects - Need more (in amount and frequency) public awareness campaigns for #clinicaltrials. - Hospitals and other healthcare institutions should be accredited as "research ready" centers of excellence where all HCPs and support staff obtain fundamental training on TCPS2 and GCPs. - #Clinicalresearch training should be provided as a basic course in undergrad life sciences programs at the University level. Future generations of physicians should be aware of the benefits of clinical trials and the importance of ongoing research as a complimentary form of providing care to patients. - Bring legal experts to the table when discussing ways to improve the review process for CDAs/NDAs, Clinical Trial Agreements, etc. The goal is to make legal review more efficient and faster. Thank you to all the presenters and panelists so far!... love the interactive and engaging sessions, plus useful workshops to plan and implement positive changes. The future looks bright when we all collaborate together! #clinicaltrial #drugdevelopment #clinicaloperations #innovativemedicines

34

3 Comments